




Searching News Database: antibody
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 19 Jan 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 1 Dec 2020
Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps
Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps
HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
HSMN NewsFeed - 7 Oct 2020
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
HSMN NewsFeed - 29 Sep 2020
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
HSMN NewsFeed - 4 Sep 2020
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
HSMN NewsFeed - 4 Sep 2020
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
HSMN NewsFeed - 24 Aug 2020
Leap Therapeutics Expands Leadership Team with Addition of Two Industry Veterans
Leap Therapeutics Expands Leadership Team with Addition of Two Industry Veterans
HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
HSMN NewsFeed - 10 Aug 2020
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
HSMN NewsFeed - 29 Jul 2020
Truvian Sciences Receives FDA Emergency Use Authorization for Easy Check COVID-19 IgM/IgG(TM) Test
Truvian Sciences Receives FDA Emergency Use Authorization for Easy Check COVID-19 IgM/IgG(TM) Test
HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
HSMN NewsFeed - 20 Jul 2020
Luminex Receives FDA Emergency Use Authorization for COVID-19 Antibody Test
Luminex Receives FDA Emergency Use Authorization for COVID-19 Antibody Test
HSMN NewsFeed - 23 Jun 2020
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
HSMN NewsFeed - 16 Jun 2020
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
HSMN NewsFeed - 9 Jun 2020
FDA Grants EUA to Rapid COVID-19 Antibody Testing Product Distributed by Premier Biotech
FDA Grants EUA to Rapid COVID-19 Antibody Testing Product Distributed by Premier Biotech
HSMN NewsFeed - 8 Jun 2020
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
HSMN NewsFeed - 8 Jun 2020
Arbor Vita Launches Open Platform COVID-19 Antibody Test Expanding Access To Higher Quality Diagnostics
Arbor Vita Launches Open Platform COVID-19 Antibody Test Expanding Access To Higher Quality Diagnostics
HSMN NewsFeed - 1 Jun 2020
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
HSMN NewsFeed - 19 May 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
HSMN NewsFeed - 15 May 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
HSMN NewsFeed - 11 May 2020
Abbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity(TM) i System
Abbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity(TM) i System
HSMN NewsFeed - 7 May 2020
FogPharma Appoints Tony Gibney as Chief Financial Officer and Chief Business Officer
FogPharma Appoints Tony Gibney as Chief Financial Officer and Chief Business Officer
HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 12 Mar 2020
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
HSMN NewsFeed - 12 Mar 2020
ImmunoPrecise Announces the Launch of PolyTope mAb Therapy(TM) to Tackle Coronavirus Pandemic
ImmunoPrecise Announces the Launch of PolyTope mAb Therapy(TM) to Tackle Coronavirus Pandemic
HSMN NewsFeed - 5 Mar 2020
Alligator Bioscience Appoints Andreas Johannesson as interim Chief Financial Officer
Alligator Bioscience Appoints Andreas Johannesson as interim Chief Financial Officer
HSMN NewsFeed - 14 Feb 2020
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
HSMN NewsFeed - 28 Jan 2020
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
HSMN NewsFeed - 8 Jan 2020
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
HSMN NewsFeed - 2 Jan 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
HSMN NewsFeed - 6 Dec 2019
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
HSMN NewsFeed - 2 Dec 2019
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
HSMN NewsFeed - 24 Oct 2019
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
HSMN NewsFeed - 18 Oct 2019
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
HSMN NewsFeed - 29 Aug 2019
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
HSMN NewsFeed - 10 Jun 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
HSMN NewsFeed - 19 Feb 2019
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
HSMN NewsFeed - 1 Feb 2019
Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
HSMN NewsFeed - 31 Jan 2019
IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors
IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors
HSMN NewsFeed - 29 Jan 2019
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
HSMN NewsFeed - 10 Jan 2019
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
HSMN NewsFeed - 28 Nov 2018
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
HSMN NewsFeed - 1 Oct 2018
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
HSMN NewsFeed - 12 Sep 2018
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
HSMN NewsFeed - 24 Aug 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
HSMN NewsFeed - 16 Aug 2018
CBT Pharmaceuticals Announces New Leadership Structure to Drive Global Expansion
CBT Pharmaceuticals Announces New Leadership Structure to Drive Global Expansion
HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
HSMN NewsFeed - 24 Jul 2018
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
HSMN NewsFeed - 9 Jul 2018
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
HSMN NewsFeed - 13 Jun 2018
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
HSMN NewsFeed - 3 May 2018
GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology
GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology
HSMN NewsFeed - 30 Apr 2018
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
HSMN NewsFeed - 26 Apr 2018
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
HSMN NewsFeed - 16 Apr 2018
Apitope Announces Positive Results with Novel Treatment for Graves' Disease
Apitope Announces Positive Results with Novel Treatment for Graves' Disease
HSMN NewsFeed - 3 Apr 2018
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
HSMN NewsFeed - 3 Apr 2018
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
HSMN NewsFeed - 14 Mar 2018
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing
HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
HSMN NewsFeed - 26 Feb 2018
GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology
GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology
HSMN NewsFeed - 22 Jan 2018
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
HSMN NewsFeed - 3 Jan 2018
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
HSMN NewsFeed - 27 Dec 2017
Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
HSMN NewsFeed - 4 Dec 2017
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
HSMN NewsFeed - 16 Nov 2017
FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
HSMN NewsFeed - 3 Oct 2017
Oncorus(R), Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer
Oncorus(R), Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 12 Sep 2017
Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
HSMN NewsFeed - 11 Sep 2017
Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof
Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof
HSMN NewsFeed - 29 Aug 2017
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
HSMN NewsFeed - 15 Aug 2017
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
HSMN NewsFeed - 14 Aug 2017
Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 17 Jul 2017
Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer
Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer
HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
HSMN NewsFeed - 9 Jun 2017
Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer
Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 24 May 2017
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
HSMN NewsFeed - 12 Apr 2017
Roche Launches Antibody Test to Aid in Diagnosis of Challenging Prostate Cancer Cases
Roche Launches Antibody Test to Aid in Diagnosis of Challenging Prostate Cancer Cases
HSMN NewsFeed - 4 Apr 2017
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
HSMN NewsFeed - 28 Mar 2017
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
HSMN NewsFeed - 3 Mar 2017
Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
HSMN NewsFeed - 9 Jan 2017
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
HSMN NewsFeed - 22 Dec 2016
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
HSMN NewsFeed - 14 Dec 2016
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
HSMN NewsFeed - 9 Dec 2016
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
HSMN NewsFeed - 21 Nov 2016
OrbusNeich Introduces a New Generation COMBO Plus Dual Therapy Stent for Active Healing
OrbusNeich Introduces a New Generation COMBO Plus Dual Therapy Stent for Active Healing
HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
HSMN NewsFeed - 22 Sep 2016
Kleo Pharmaceuticals Inc. Appoints David A. Spiegel as Chief Executive Officer
Kleo Pharmaceuticals Inc. Appoints David A. Spiegel as Chief Executive Officer
HSMN NewsFeed - 22 Sep 2016
Kleo Pharmaceuticals Inc. Appoints Roy Prieb as Chief Operating Officer and Chief Financial Officer
Kleo Pharmaceuticals Inc. Appoints Roy Prieb as Chief Operating Officer and Chief Financial Officer
HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 1 Aug 2016
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
HSMN NewsFeed - 22 Jul 2016
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
HSMN NewsFeed - 22 Jul 2016
ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer
ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
HSMN NewsFeed - 8 Jul 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
HSMN NewsFeed - 9 Jun 2016
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
HSMN NewsFeed - 11 May 2016
Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
HSMN NewsFeed - 9 May 2016
Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs
Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs
HSMN NewsFeed - 5 May 2016
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership Appointments
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership Appointments
HSMN NewsFeed - 3 May 2016
XBiotech Appoints Amgen Veteran Scott Whitehurst as Chief Financial Officer
XBiotech Appoints Amgen Veteran Scott Whitehurst as Chief Financial Officer
HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
HSMN NewsFeed - 6 Apr 2016
Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai Inc.
Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai Inc.
HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
HSMN NewsFeed - 23 Mar 2016
Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing
Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing
HSMN NewsFeed - 21 Mar 2016
FDA approves expanded use of Roche hepatitis C virus RNA test as aid in diagnosis
FDA approves expanded use of Roche hepatitis C virus RNA test as aid in diagnosis
HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
HSMN NewsFeed - 26 Feb 2016
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 9 Feb 2016
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
HSMN NewsFeed - 25 Jan 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 12 Jan 2016
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 19 Nov 2015
Oncimmune Appoints Dr James Jett, World Recognised Lung Cancer Specialist, as Chief Medical Officer
Oncimmune Appoints Dr James Jett, World Recognised Lung Cancer Specialist, as Chief Medical Officer
Additional items found! 500

Members Archive contains
500 additional stories matching:
antibody
(Password required)
antibody
(Password required)